Filspari Tablet, Film Coated
Product Images NDC 68974-200

7 FDA label images from Travere Therapeutics, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Filspari (NDC 68974-200). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Travere Therapeutics, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Sparsentan Structure (Sparsentan Structure)

Sparsentan Structure (Sparsentan Structure)
Chemical structure diagram of sparsentan, the active ingredient in FILSPARI. The structure shows multiple aromatic rings, a sulfonamide group, and heterocyclic components characteristic of the molecule.*
FDA Label Image

Figure 1 (Figure 1)

Figure 1 (Figure 1)
A line graph comparing the adjusted geometric mean percent change over 36 weeks between FILSPARI (sparsentan) and irbesartan. FILSPARI shows a steeper decline in percent change compared to irbesartan, with data points and confidence intervals plotted at multiple visit weeks (baseline, 4, 6, 12, 24, and 36). Sample sizes for each week and drug are indicated below the x-axis.*
FDA Label Image

Figure 2 (Figure 2)

Figure 2 (Figure 2)
Line graph comparing the least squares (LS) mean change with 95% confidence intervals over time for FILSPARI (sparsentan) and Irbesartan. The x-axis shows time points from baseline (BL) to day 110, and the y-axis represents LS mean change values. FILSPARI is shown with a solid red line and circles, while Irbesartan is depicted with a dashed blue line and triangles. Subject numbers for each treatment group at various time points are shown below the x-axis.*
FDA Label Image

Figure 3 (Figure 3)

Figure 3 (Figure 3)
Line graph comparing the least squares mean change with 95% confidence intervals for FILSPARI (sparsentan) and Irbesartan over a time period from baseline to 108 weeks. The x-axis shows time points in weeks with patient counts at each, and the y-axis represents the LS mean change values. FILSPARI data is shown with solid red lines and circles, while Irbesartan is shown with dashed blue lines and triangles.*
FDA Label Image

Figure 4 (Figure 4)

Figure 4 (Figure 4)
A line graph comparing the geometric least squares (LS) mean percent change with 95% confidence intervals over time between FILSPARI (sparsentan) and Irbesartan. The x-axis shows time in weeks from baseline (BL) to week 108. The y-axis represents percent change. Two lines plot the data: FILSPARI with red circles and Irbesartan with blue triangles.*
FDA Label Image

Principal Display Panel (200 mg Tablet Label)

Principal Display Panel (200 mg Tablet Label)
FILSPARI (sparsentan) film-coated tablets 200 mg oral dosage form. The label shows the product name, active ingredient, strength, and quantity of 30 tablets. It includes directions for storage and a note to dispense the accompanying medication guide. Manufactured for Travere Therapeutics, Inc., and by Catalent in Kansas City, MO. The label contains a barcode, QR code, expiration date placeholder, and lot number placeholder.*
FDA Label Image

Principal Display Panel (400 mg Tablet Label)

Principal Display Panel (400 mg Tablet Label)
FILSPARI 400 mg (sparsentan) film-coated tablets packaging label showing 30 tablets per container. The label includes dosage strength, NDC 68974-400-30, Rx only, manufacturer Travere Therapeutics, Inc., and manufacturer Catalent with their locations, and storage instructions. A QR code and barcode are also visible on the label.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.